Comparison of two genotypic algorithms to determine HIV-1 tropism

HIV Medicine

Volumn 9, Issue 1, 2008, Pages 1-5

  Soulié, Cathia ^a   Derache, A ^a   Aime C ^a   Marcelin, A G ^a   Carcelain, G ^a   Simon, A ^a   Katlama, C ^a   Calvez, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

B subtype; CCR5co receptor; CXCR4 co receptor; Genotype; Tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC ALGORITHM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SEQUENCE ANALYSIS; VALIDATION PROCESS; VIRUS ENVELOPE;

ADULT; AGED; ALGORITHMS; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ANALYSIS, DNA; TROPISM; VIRAL LOAD;

EID: 38349075744     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00518.x     Document Type: Article

References (26)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
2. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20: 1359-1367.
3. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000; 14: 2937-2939.
4. Jensen MA, van 't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5: 104-112.
5. Fouchier RA, Groenink M, Kootstra NA et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66: 3183-3187.
6. Tersmette M, de Goede RE, Al BJ et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62: 2026-2032.
7. Schuitemaker H, Koot M, Kootstra NA et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66: 1354-1360.
8. Koot M, Keet IP, Vos AH et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-688.
9. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968-974.
10. Fricker SP, Anastassov V, Cox J et al. Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006; 72: 588-596.
11. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17: 7-16.
12. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20: 111-126.
13. Mayer H, Van der Ryst E, Saag M et al. Safety and efficacy of Maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual mixed-tropic HIV-1: 24 week results of phase2b exploratory trial. IAS; 2006; Abstract THLB0215 Toronto; 2006.
14. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001; 288: 51-62.
15. Jensen MA, Li FS, van 't Wout AB et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-13388.
16. Beerenwinkel N, Sing T, Lengauer T et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005; 21: 3943-3950.
17. Skrabal K, Low AJ, Dong W et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: Degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45: 279-284.
18. Rizzuto CD, Wyatt R, Hernandez-Ramos N et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (New York, NY) 1998; 280: 1949-1953.
19. Groenink M, Fouchier RA, Broersen S et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science (New York, NY) 1993; 260: 1513-1516.
20. Jansson M, Backstrom E, Scarlatti G et al. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2001; 17: 1405-1414.
21. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-872.
22. Garrido C, Aguilera A, Skrabal K et al. Prevalence of X4 viruses in patients infected with HIV-1 non-B subtypes. Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, USA; 2007.
23. Brumme ZL, Goodrich J, Mayer HB et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192: 466-474.
24. Hunt PW, Harrigan PR, Huang W et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194: 926-930.
25. Delobel P, Sandres-Saune K, Cazabat M et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 382-392.
26. Koot M, Vos AH, Keet RP et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6: 49-54.